169808-00-8

Basic information

• Product Name: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile
• Synonyms: 4-(4-METHYL-2,5-DIOXOIMIDAZOLIDIN-4-YL)BENZONITRILE(WXG01512)
• CAS NO: 169808-00-8
• Molecular Formula: C₁₁H₉N₃O₂
• Molecular Weight: 215.2081
• Mol File: 169808-00-8.mol
• Article Data: 9

Chemical Properties

• Density: 1.37g/cm³
• Refractive Index: 1.623
• CAS DataBase Reference: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile(169808-00-8)
• EPA Substance Registry System: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile(169808-00-8)

Safety Data

• Hazardous Substances Data: 169808-00-8(Hazardous Substances Data)

Upstream product

• 1443-80-7 4-cyanophenyl methyl ketone 
• 506-87-6 ammonium carbonate 
• 616-38-6 carbonic acid dimethyl ester 
• 151-50-8 potassium cyanide 

Relevant articles and documents

Identification and Profiling of Hydantoins - A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-d-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists

The present invention relates to compounds of the formula I which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes

Heterocyclic compounds, their preparation and their use as leucocyte adhesion inhibitors and VLA-4-antagonists

Compounds of the formula I, in which B, E, W, Y, Z, R, R2, R2a, R2b, R3, g and h have the meanings indicated in the specifications. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the thera